

JAN 11 2007

Application No. 09/637,774  
Amendment dated January 11, 2007


Docket No.: 42982C1C(47843)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1-24. (Canceled)

25. (Currently amended) A method for treating a disorder of the nervous system in which the pathophysiology of the disorder involves excessive or inappropriate release of a neurotransmitter from neuronal cells, comprising administering to a mammal exhibiting symptoms of the disorder or susceptible to the disorder an effective amount of a compound of the following formula



wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, ~~or a substituted or unsubstituted aralkyl having at least about 5 ring atoms,~~ or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;

R<sup>1</sup> is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms; and pharmaceutically acceptable salts thereof.

26. (Previously presented) A method of claim 25 wherein at least one of R and R<sup>1</sup> is substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

27. (Previously presented) A method of claim 25 wherein both R and R<sup>1</sup> are substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

Application No. 09/637,774  
Amendment dated January 11, 2007

Docket No.: 42982C1C(47843)

28. (Canceled)

29. (Previously presented) A method of claim 25 wherein R and R<sup>1</sup> are substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl or substituted or unsubstituted benzyl.

30. (Previously presented) A method of claim 25 wherein the compound is selected from the group consisting of:

N-(4-*sec*-butylphenyl)-N-benzylguanidine;  
N-(5-acenaphthyl)-N-benzylguanidine;  
N-(3-acenaphthyl)-N-benzylguanidine;  
N-(5-acenaphthyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(3-acenaphthyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(4-cyclohexylphenyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(4-cyclohexylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(2-fluorenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-*sec*-butylphenyl)-N-(cinnamylmethylene)guanidine;  
N-(4-*n*-butoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-biphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-indanyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-trifluoromethoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-*sec*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(methoxy-1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-chloro-1-naphthyl)-N-(4-*tert*-benzyl)guanidine;  
N-(4-*tert*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(1-naphthylmethyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(3-phenoxybenzyl)guanidine;


Application No. 09/637,774  
Amendment dated January 11, 2007

Docket No.: 42982C1C(47843)

N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;  
N-(5-acenaphthyl)-N-(cinnamyl)guanidine;  
N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;  
N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;  
and pharmaceutically acceptable salts thereof.

31. (Previously presented) A method of any one of claims 25 through 30 wherein the mammal is suffering from a neurodegenerative disorder.

32. (Previously presented) A method for treating a mammal suffering from or susceptible to a neurodegenerative disease, comprising administering to the mammal an effective amount of a compound of the following formula



wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;

R<sup>1</sup> is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms; and pharmaceutically acceptable salts thereof.

33. (Previously presented) A method of claim 32 wherein at least one of R and R<sup>1</sup> is substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

Application No. 09/637,774  
Amendment dated January 11, 2007

Docket No.: 42982C1C(47843)

34. (Previously presented) A method of claim 32 wherein both R and R<sup>1</sup> are substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

35. (Canceled)

36. (Previously presented) A method of claim 32 wherein R and R<sup>1</sup> are substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl or substituted or unsubstituted benzyl.

37. (Previously presented) A method of claim 32 wherein the compound is selected from the group consisting of:

N-(4-*sec*-butylphenyl)-N-benzylguanidine;  
N-(5-acenaphthyl)-N-benzylguanidine;  
N-(3-acenaphthyl)-N-benzylguanidine;  
N-(5-acenaphthyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(3-acenaphthyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(4-cyclohexylphenyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(4-cyclohexylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(2-fluorenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-*sec*-butylphenyl)-N-(cinnamylmethylene)guanidine;  
N-(4-*n*-butoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-biphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-indanyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-trifluoromethoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-*sec*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(methoxy-1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-chloro-1-naphthyl)-N-(4-*tert*-benzyl)guanidine;  
N-(4-*tert*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;


Application No. 09/637,774  
Amendment dated January 11, 2007

Docket No.: 42982C1C(47843)

N-(4-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(1-naphthylmethyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(3-phenoxybenzyl)guanidine;  
N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;  
N-(5-acenaphthyl)-N-(cinnamyl)guanidine;  
N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;  
N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;  
and pharmaceutically acceptable salts thereof.

38. (Previously presented) A method of any one of claims 32-34 or 36-37 wherein the neurodegenerative disease is Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Down's Syndrome, Korsakoff's disease, olivopontocerebellar atrophy, HIV-induced dementia or blindness, multi-infarct dementia or diabetic neuropathy.

39. (Previously presented) A method of treating a disease in which the pathophysiology of the disease involves inappropriate cellular secretion comprising administering to a mammal suffering from or susceptible to the disease an effective amount of a compound of the following formula



wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;

R<sup>1</sup> is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring

Application No. 09/637,774  
Amendment dated January 11, 2007

Docket No.: 42982C1C(47843)

members in each ring and from 1 to 3 hetero atoms; and pharmaceutically acceptable salts thereof.

40. (Previously presented) A method of claim 39 wherein at least one of R and R<sup>1</sup> is substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

41. (Previously presented) A method of claim 39 wherein both R and R<sup>1</sup> are substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

42. (Canceled)

43. (Previously presented) A method of claim 39 wherein R and R<sup>1</sup> are substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl or substituted or unsubstituted benzyl.

44. (Previously presented) A method of claim 39 wherein the compound is selected from the group consisting of:


N-(4-*sec*-butylphenyl)-N-benzylguanidine;  
N-(5-acenaphthyl)-N-benzylguanidine;  
N-(3-acenaphthyl)-N-benzylguanidine;  
N-(5-acenaphthyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(3-acenaphthyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(4-cyclohexylphenyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(4-cyclohexylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(2-fluorenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-*sec*-butylphenyl)-N-(cinnamylmethylene)guanidine;  
N-(4-*n*-butoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-biphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-indanyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-trifluoromethoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-*sec*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;

Application No. 09/637,774  
Amendment dated January 11, 2007

Docket No.: 42982C1C(47843)

N-(3-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(methoxy-1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-chloro-1-naphthyl)-N-(4-*tert*-benzyl)guanidine;  
N-(4-*tert*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(1-naphthylmethyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(3-phenoxybenzyl)guanidine;  
N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;  
N-(5-acenaphthyl)-N-(cinnamyl)guanidine;  
N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;  
N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;  
and pharmaceutically acceptable salts thereof.

45. (Previously presented) A method of modulating the release of excess endogenous neurotransmitters from a mammal comprising administering to the mammal an effective amount of a compound of the following formula



wherein R is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, or substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;

R<sup>1</sup> is substituted or unsubstituted carbocyclic aryl having at least about 5 ring atoms, substituted or unsubstituted aralkyl having at least about 5 ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring

Application No. 09/637,774  
Amendment dated January 11, 2007

Docket No.: 42982C1C(47843)

members in each ring and from 1 to 3 hetero atoms; and pharmaceutically acceptable salts thereof.

46. (Previously presented) A method of claim 45 wherein at least one of R and R<sup>1</sup> is substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

47. (Previously presented) A method of claim 45 wherein both R and R<sup>1</sup> are substituted or unsubstituted carbocyclic aryl or substituted or unsubstituted aralkyl.

48. (Canceled)

49. (Previously presented) A method of claim 45 wherein R and R<sup>1</sup> are substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl or substituted or unsubstituted benzyl.

50. (Previously presented) A method of claim 45 wherein the compound is selected from the group consisting of:

N-(4-*sec*-butylphenyl)-N-benzylguanidine;  
N-(5-acenaphthyl)-N-benzylguanidine;  
N-(3-acenaphthyl)-N-benzylguanidine;  
N-(5-acenaphthyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(3-acenaphthyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(4-cyclohexylphenyl)-N-(4-*isopropylbenzyl*)guanidine;  
N-(4-cyclohexylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(2-fluorenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-*sec*-butylphenyl)-N-(cinnamylmethylene)guanidine;  
N-(4-*n*-butoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-biphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-indanyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-trifluoromethoxyphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-*sec*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;



Application No. 09/637,774  
Amendment dated January 11, 2007

Docket No.: 42982C1C(47843)

N-(3-acenaphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(methoxy-1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(1-naphthyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-chloro-1-naphthyl)-N-(4-*tert*-benzyl)guanidine;  
N-(4-*tert*-butylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(4-iodophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(1-naphthylmethyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(3-phenoxybenzyl)guanidine;  
N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;  
N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;  
N-(5-acenaphthyl)-N-(cinnamyl)guanidine;  
N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;  
N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;  
and pharmaceutically acceptable salts thereof.

51-59. (Canceled)